Inherited Variants Affecting RNA Editing May Contribute to Ovarian Cancer Susceptibility: Results from a Large-Scale Collaboration.
Jennifer B Permuth,Brett Reid,Madalene Earp,Y Ann Chen,Alvaro N A Monteiro,Zhihua Chen,AOCS Study Group,Georgia Chenevix-Trench,Peter A Fasching,Matthias W Beckmann,Diether Lambrechts,Adriaan Vanderstichele,Els Van Niewenhuyse,Ignace Vergote,Mary Anne Rossing,Jennifer Anne Doherty,Jenny Chang-Claude,Kirsten Moysich,Kunle Odunsi,Marc T Goodman,Yurii B Shvetsov,Lynne R Wilkens,Pamela J Thompson,Thilo Dörk,Natalia Bogdanova,Ralf Butzow,Heli Nevanlinna,Liisa Pelttari,Arto Leminen,Francesmary Modugno,Robert P Edwards,Roberta B Ness,Joseph Kelley,Florian Heitz,Beth Karlan,Jenny Lester,Susanne K Kjaer,Allan Jensen,Graham Giles,Michelle Hildebrandt,Dong Liang,Karen H Lu,Xifeng Wu,Douglas A Levine,Maria Bisogna,Andrew Berchuck,Daniel W Cramer,Kathryn L Terry,Shelley S Tworoger,Elizabeth M Poole,Elisa V Bandera,Brooke Fridley,Julie Cunningham,Stacey J Winham,Sara H Olson,Irene Orlow,Line Bjorge,Lambertus A Kiemeney,Leon Massuger,Tanja Pejovic,Melissa Moffitt,Nhu Le,Linda S Cook,Angela Brooks-Wilson,Linda E Kelemen,Jacek Gronwald,Jan Lubinski,Nicolas Wentzensen,Louise A Brinton,Jolanta Lissowska,Hanna Yang,Estrid Hogdall,Claus Hogdall,Lene Lundvall,Paul D P Pharoah,Honglin Song,Ian Campbell,Diana Eccles,Iain McNeish,Alice Whittemore,Valerie McGuire,Weiva Sieh,Joseph Rothstein,Catherine M Phelan,Harvey Risch,Steven Narod,John McLaughlin,Hoda Anton-Culver,Argyrios Ziogas,Usha Menon,Simon Gayther,Susan J Ramus,Aleksandra Gentry-Maharaj,Celeste Leigh Pearce,Anna H Wu,Jolanta Kupryjanczyk,Agnieszka Dansonka-Mieszkowska,Joellen M Schildkraut,Jin Q Cheng,Ellen L Goode,Thomas A Sellers
DOI: https://doi.org/10.18632/oncotarget.10546
2016-01-01
Oncotarget
Abstract:RNA editing in mammals is a form of post-transcriptional modification in which adenosine is converted to inosine by the adenosine deaminases acting on RNA (ADAR) family of enzymes. Based on evidence of altered ADAR expression in epithelial ovarian cancers (EOC), we hypothesized that single nucleotide polymorphisms (SNPs) in ADAR genes modify EOC susceptibility, potentially by altering ovarian tissue gene expression. Using directly genotyped and imputed data from 10,891 invasive EOC cases and 21,693 controls, we evaluated the associations of 5,303 SNPs in ADAD1, ADAR, ADAR2, ADAR3, and SND1. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI), with adjustment for European ancestry. We conducted gene-level analyses using the Admixture Maximum Likelihood (AML) test and the Sequence-Kernel Association test for common and rare variants (SKAT-CR). Association analysis revealed top risk-associated SNP rs77027562 (OR (95% CI)= 1.39 (1.17-1.64), P=1.0x10-4) in ADAR3 and rs185455523 in SND1 (OR (95% CI)= 0.68 (0.56-0.83), P=2.0x10-4). When restricting to serous histology (n=6,500), the magnitude of association strengthened for rs185455523 (OR=0.60, P=1.0x10-4). Gene-level analyses revealed that variation in ADAR was associated (P<0.05) with EOC susceptibility, with PAML=0.022 and PSKAT-CR=0.020. Expression quantitative trait locus analysis in EOC tissue revealed significant associations (P<0.05) with ADAR expression for several SNPs in ADAR, including rs1127313 (G/A), a SNP in the 3' untranslated region. In summary, germline variation involving RNA editing genes may influence EOC susceptibility, warranting further investigation of inherited and acquired alterations affecting RNA editing.